The primary purpose of this study is to:
Demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is
superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately
controlled with telmisartan 40 mg monotherapy.